KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Current Assets (2017 - 2025)

Bionano Genomics (BNGO) has disclosed Current Assets for 9 consecutive years, with $45.4 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 14.93% to $45.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $45.4 million through Dec 2025, up 14.93% year-over-year, with the annual reading at $45.4 million for FY2025, 14.93% up from the prior year.
  • Current Assets hit $45.4 million in Q4 2025 for Bionano Genomics, down from $48.8 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $370.3 million in Q1 2021 to a low of $39.5 million in Q4 2024.
  • Historically, Current Assets has averaged $154.3 million across 5 years, with a median of $131.3 million in 2023.
  • Biggest five-year swings in Current Assets: soared 2080.26% in 2021 and later plummeted 71.82% in 2024.
  • Year by year, Current Assets stood at $272.4 million in 2021, then plummeted by 42.26% to $157.3 million in 2022, then dropped by 10.92% to $140.1 million in 2023, then tumbled by 71.82% to $39.5 million in 2024, then increased by 14.93% to $45.4 million in 2025.
  • Business Quant data shows Current Assets for BNGO at $45.4 million in Q4 2025, $48.8 million in Q3 2025, and $42.7 million in Q2 2025.